# US 2025/0082783 A1 · Compositions and methods for prevention and treatment of genetic disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082783 A1
- Document ID: US20250082783A1
- Status: Published application
- Kind: A1
- Application number: 18/890,368
- Filed: 2024-09-19
- Published: 2025-03-13
- Earliest claimed: 2022-03-22
- Assignees: Children's Medical Center Corporation
- Applicants: The Children's Medical Center Corporation
- Inventors: Dario O. Fauza
- Web page: https://patentgrep.com/patent/US20250082783A1

## CPC

- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 38/1709: {from mammals}
- A61K 38/395: {Alveolar surfactant peptides; Pulmonary surfactant peptides}
- A61K 48/0025: {wherein the non-active part clearly interacts with the delivered nucleic acid}
- A61K 48/0033: {the non-active part being non-polymeric}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61P 11/00: Drugs for disorders of the respiratory system
- C07K 14/4712: {Cystic fibrosis}
- C07K 14/785: Alveolar surfactant peptides; Pulmonary surfactant peptides
- A61K 48/0041: {the non-active part being polymeric}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Methods and compositions for the transamniotic delivery of mRNA encoding cystic fibrosis transmembrane conductance regulator protein or surfactant protein B to a fetus for the prenatal treatment of cystic fibrosis or a surfactant protein B deficiency.

## Claims

### Claim 1

A method for treating cystic fibrosis in a developing fetus, the method comprising: administering to the amniotic fluid surrounding a developing fetus an mRNA molecule encoding a cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide, thereby treating cystic fibrosis in the developing fetus.

### Claim 2 (depends on 1)

The method of claim 1, wherein the mRNA is translated in the lungs and/or intestines of the fetus to produce the CFTR polypeptide in lung cells of the fetus.

### Claim 3 (depends on 1)

The method of claim 1, wherein the method comprises reducing the incidence of meconium ileus in the fetus or the child developed from the fetus.

### Claim 4

A method for treating a disease or disorder associated with a surfactant protein B (SPB) deficiency in a developing fetus, the method comprising: administering to the amniotic fluid surrounding a developing fetus an mRNA molecule encoding an SPB polypeptide, thereby treating the disease or disorder associated with SPB deficiency in the developing fetus.

### Claim 5 (depends on 4)

The method of claim 4, wherein the disease or disorder is prematurity or congenital surfactant protein B deficiency.

### Claim 6 (depends on 4)

The method of claim 4, wherein the mRNA is translated in small bowel cells or lungs of the fetus to produce the SPB polypeptide in small bowel cells of the fetus or in lungs of the fetus, respectively.

### Claim 7 (depends on 4)

The method of claim 4, wherein the method is associated with an increase in levels of phosphatidylcholine in the amniotic fluid.

### Claim 8 (depends on 1)

The method of claim 1, wherein the mRNA is administered using a lipid nanoparticle or a lipopolyplex.

### Claim 9 (depends on 1)

The method of claim 1, wherein the fetus is a human fetus.

### Claim 10 (depends on 1)

The method of claim 1, wherein the mRNA is administered prior to 10 weeks of pregnancy.

### Claim 11 (depends on 1)

The method of claim 1, wherein the mRNA is administered prior to 5 weeks of pregnancy.

### Claim 12 (depends on 1)

The method of claim 1, wherein the mRNA is administered after 10 weeks of pregnancy.

### Claim 13 (depends on 1)

The method of claim 1, wherein the administering is associated with the presence of and/or an increase in levels of the mRNA in a tissue of the fetus.

### Claim 14 (depends on 13)

The method of claim 13, wherein the tissue comprises liver, stomach, intestines, pancreas, spleen, thymus, lymph nodes, brain, meninges, heart, blood vessels, lungs, airways, kidneys, ureters, urethra, ovaries, testicles, genitalia, skin, skin annexes, muscle, bone, cartilage, bone marrow, eyes, ears, mouth, nose, pharynx, larynx, vitreous body, cerebrospinal fluid, and peripheral blood.

### Claim 15 (depends on 14)

The method of claim 14, wherein the tissue comprises liver, stomach, intestines, lungs, and/or blood.

### Claim 16 (depends on 4)

The method of claim 4, wherein the administration is associated with the presence of and/or an increase in levels of the mRNA in amniotic fluid, amnion, chorion, umbilical cord, and/or placenta associated with the fetus.

### Claim 17 (depends on 1)

A kit suitable for use in treating a disease or disorder, wherein the kit comprises the mRNA of claim 1.

### Claim 18

A method for delivering one or more mRNA molecules to the bloodstream of a developing fetus, the method comprising: administering to the amniotic fluid surrounding the developing fetus an mRNA molecule encoding a polypeptide that has reduced expression and/or activity in the developing fetus relative to a healthy developing fetus.

### Claim 19 (depends on 18)

The method of claim 18, wherein the mRNA is translated in an organ and/or tissue of the developing fetus, thereby treating the developing fetus for a disease or disorder associated with the polypeptide.

### Claim 20 (depends on 18)

The method of claim 18, wherein the polypeptide is surfactant protein A, B, C, or D.
